Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BICALUTAMIDE Cause Condition aggravated? 111 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 111 reports of Condition aggravated have been filed in association with BICALUTAMIDE (Bicalutamide). This represents 2.7% of all adverse event reports for BICALUTAMIDE.

111
Reports of Condition aggravated with BICALUTAMIDE
2.7%
of all BICALUTAMIDE reports
4
Deaths
64
Hospitalizations

How Dangerous Is Condition aggravated From BICALUTAMIDE?

Of the 111 reports, 4 (3.6%) resulted in death, 64 (57.7%) required hospitalization, and 1 (0.9%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BICALUTAMIDE. However, 111 reports have been filed with the FAERS database.

What Other Side Effects Does BICALUTAMIDE Cause?

Malignant neoplasm progression (352) Prostatic specific antigen increased (322) Drug ineffective (268) Fatigue (258) Prostate cancer (258) Asthenia (223) Hot flush (219) Off label use (171) Disease progression (169) Anaemia (164)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which BICALUTAMIDE Alternatives Have Lower Condition aggravated Risk?

BICALUTAMIDE vs BICTEGRAVIR BICALUTAMIDE vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM BICALUTAMIDE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS BICALUTAMIDE vs BILASTINE

Related Pages

BICALUTAMIDE Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated BICALUTAMIDE Demographics